These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 25366031)

  • 1. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy.
    Jonnalagadda M; Mardiros A; Urak R; Wang X; Hoffman LJ; Bernanke A; Chang WC; Bretzlaff W; Starr R; Priceman S; Ostberg JR; Forman SJ; Brown CE
    Mol Ther; 2015 Apr; 23(4):757-68. PubMed ID: 25366031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.
    Hombach A; Hombach AA; Abken H
    Gene Ther; 2010 Oct; 17(10):1206-13. PubMed ID: 20555360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo.
    He H; Vedia RA; Lu S; Li Q; Cox KR; St John L; Sergeeva A; Clise-Dwyer K; Alatrash G; Shpall EJ; Ma Q; Molldrem JJ
    Cytotherapy; 2024 Nov; 26(11):1331-1340. PubMed ID: 39033444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2-CH3 IgG spacer domains.
    Proff J; Brey CU; Ensser A; Holter W; Lehner M
    J Transl Med; 2018 Feb; 16(1):26. PubMed ID: 29422056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
    Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.
    Almåsbak H; Walseng E; Kristian A; Myhre MR; Suso EM; Munthe LA; Andersen JT; Wang MY; Kvalheim G; Gaudernack G; Kyte JA
    Gene Ther; 2015 May; 22(5):391-403. PubMed ID: 25652098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G-opsonized target cells.
    D'Aloia MM; Caratelli S; Palumbo C; Battella S; Arriga R; Lauro D; Palmieri G; Sconocchia G; Alimandi M
    Cytotherapy; 2016 Feb; 18(2):278-90. PubMed ID: 26705740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.
    Hudecek M; Sommermeyer D; Kosasih PL; Silva-Benedict A; Liu L; Rader C; Jensen MC; Riddell SR
    Cancer Immunol Res; 2015 Feb; 3(2):125-35. PubMed ID: 25212991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.
    Bishop DC; Xu N; Tse B; O'Brien TA; Gottlieb DJ; Dolnikov A; Micklethwaite KP
    Mol Ther; 2018 Aug; 26(8):1883-1895. PubMed ID: 29861327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
    Hudecek M; Lupo-Stanghellini MT; Kosasih PL; Sommermeyer D; Jensen MC; Rader C; Riddell SR
    Clin Cancer Res; 2013 Jun; 19(12):3153-64. PubMed ID: 23620405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
    Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes.
    Schäfer D; Henze J; Pfeifer R; Schleicher A; Brauner J; Mockel-Tenbrinck N; Barth C; Gudert D; Al Rawashdeh W; Johnston ICD; Hardt O
    Front Immunol; 2020; 11():1704. PubMed ID: 32849600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing.
    Qian L; Li D; Ma L; He T; Qi F; Shen J; Lu XA
    Cell Immunol; 2016; 304-305():49-54. PubMed ID: 26996927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
    Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents.
    Sharifzadeh Z; Rahbarizadeh F; Shokrgozar MA; Ahmadvand D; Mahboudi F; Jamnani FR; Moghimi SM
    Cancer Lett; 2013 Jul; 334(2):237-44. PubMed ID: 22902507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hu8F4-CAR T cells with mutated Fc spacer segment improve target-specificity and mediate anti-leukemia activity
    Molldrem J; He H; Vedia R; Lu S; Li Q; Cox K; St John L; Sergeeva A; Clise-Dwyer K; Alatrash G; Shpall E; Ma Q
    Res Sq; 2024 Feb; ():. PubMed ID: 38464203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors.
    De Oliveira SN; Wang J; Ryan C; Morrison SL; Kohn DB; Hollis RP
    J Transl Med; 2013 Jan; 11():23. PubMed ID: 23360526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
    Ma Q; Gomes EM; Lo AS; Junghans RP
    Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
    Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
    Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.